Nutrition Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Clin Nutr. 2020 Mar;39(3):789-819. doi: 10.1016/j.clnu.2019.04.004. Epub 2019 Apr 17.
The current systematic review and meta-analysis investigated the effect of probiotic/synbiotic on a wide range of inflammatory and anti-inflammatory markers in healthy and various disease conditions. PubMed, SCOPUS and Web of Science databases were searched. All clinical trials which investigated the effect of oral administration of probiotic or synbiotic on inflammatory markers (C-reactive protein (CRP), interleukin (IL) 1β, IL-4, IL-6, IL-8, IL-10, IL-12, tumor necrosis factor (TNF) α, interferon (IFN) γ and transforming growth factor (TGF) β) for more than one week with concurrent control groups were included. One-hundred sixty seven publications was analysed. Results were as follows: CRP decreased in healthy, metabolic disorders, inflammatory bowel disease (IBD), arthritis and critically ill condition but not in renal failure. IL-1B: no change in healthy subjects and arthritis. TNF-α: decreased in healthy, fatty liver, IBD and hepatic cirrhosis, no change in diabetes, metabolic syndrome (MS) + PCOS (polycystic ovary syndrome) and arthritis. IL-6: no change in healthy, metabolic disorders and arthritis, increased in cirrhosis and renal failure, decreased in PCOS + MS. IL-10: no change in healthy, IBD and metabolic disorders, increased in arthritis. IL-4, IL-8, IL-12, IFN-g and TGF-b: no change in healthy subjects. In conclusion, probiotic/synbiotic decreased some of the inflammatory markers. The intervention was most effective in CRP and TNF-α reduction in healthy or disease state. Moreover, the intervention decreased inflammation most effectively in the following disease conditions, respectively: IBD, arthritis, fatty liver. PROSPERO REGISTRATION NUMBER: CRD42018088688.
本系统评价和荟萃分析研究了益生菌/合生菌对健康和各种疾病状态下广泛的炎症和抗炎标志物的影响。检索了 PubMed、SCOPUS 和 Web of Science 数据库。纳入了所有临床试验，这些试验调查了口服益生菌或合生菌对炎症标志物（C 反应蛋白（CRP）、白细胞介素（IL）1β、IL-4、IL-6、IL-8、IL-10、IL-12、肿瘤坏死因子（TNF）α、干扰素（IFN）γ和转化生长因子（TGF）β）的影响，持续时间超过一周，并伴有同期对照组。分析了 167 篇文献。结果如下：CRP 在健康、代谢紊乱、炎症性肠病（IBD）、关节炎和危重病患者中降低，但在肾衰竭患者中不降低。IL-1B：在健康受试者和关节炎患者中无变化。TNF-α：在健康、脂肪肝、IBD 和肝硬化患者中降低，在糖尿病、代谢综合征（MS）+多囊卵巢综合征（PCOS）和关节炎患者中无变化。IL-6：在健康、代谢紊乱和关节炎患者中无变化，在肝硬化和肾衰竭患者中增加，在 PCOS+MS 患者中减少。IL-10：在健康、IBD 和代谢紊乱患者中无变化，在关节炎患者中增加。IL-4、IL-8、IL-12、IFN-g 和 TGF-b：在健康受试者中无变化。总之，益生菌/合生菌降低了一些炎症标志物。干预措施在健康或疾病状态下降低 CRP 和 TNF-α最有效。此外，该干预措施在以下疾病状况下最有效地减轻炎症，分别为：IBD、关节炎、脂肪肝。PROSPERO 注册号：CRD42018088688。
